Drug intelligence / Profile preview

fascin inhibitor

Development stage: Unknown
Lead developer: Protheragen
Modality: Small Molecules
Administration: Intraperitoneal

Overview

Fascin inhibitors are a class of small molecule therapeutics designed to target and inhibit the actin-bundling protein fascin, specifically the fascin-1 isoform. Fascin-1 is frequently overexpressed in various metastatic cancers and is essential for the formation of filopodia, which are cellular protrusions that facilitate tumor cell migration and invasion. By blocking the actin-bundling activity of fascin, these inhibitors aim to reduce the metastatic potential of cancer cells and improve patient outcomes. Protheragen is developing a fascin inhibitor as a small molecule therapeutic for the treatment of cancer, which is currently in Phase I clinical development.

Other names: fascin inhibitorfascin-1 inhibitorfascin1 inhibitorfascin 1 inhibitor

Targets

FSCN1

Beyond the preview

Go deeper on fascin inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fascin inhibitor.

Explore the full profile